MinichMacGregor Wealth Management LLC Purchases 4,318 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

MinichMacGregor Wealth Management LLC lifted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 83,718 shares of the medical equipment provider’s stock after purchasing an additional 4,318 shares during the period. MinichMacGregor Wealth Management LLC owned 0.12% of Lantheus worth $7,489,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after buying an additional 32,551 shares in the last quarter. Moloney Securities Asset Management LLC purchased a new stake in shares of Lantheus during the 3rd quarter valued at $1,066,000. Massachusetts Financial Services Co. MA bought a new stake in Lantheus in the third quarter worth about $25,955,000. Van ECK Associates Corp raised its holdings in shares of Lantheus by 58.6% in the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after purchasing an additional 21,604 shares during the period. Finally, Swedbank AB lifted its position in shares of Lantheus by 21.1% during the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock valued at $79,266,000 after buying an additional 125,843 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on LNTH shares. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Stock Up 1.4 %

NASDAQ LNTH opened at $95.39 on Thursday. The company has a market capitalization of $6.63 billion, a price-to-earnings ratio of 15.87 and a beta of 0.46. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The stock’s 50-day simple moving average is $90.36 and its two-hundred day simple moving average is $100.29.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.